The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

Phase III Gazyva Trial Fails to Meet Primary Endpoint of Improving PFS in DLBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A phase III study evaluating Gazyva (obinutuzumab) plus CHOP chemotherapy in people with previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint of progression-free survival compared to Rituxan (rituximab) plus CHOP chemotherapy, according to Genentech, a member of the Roche Group.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Guest Editorial

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer. 
By E. Anders Kolb
Clinical Roundup

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account